Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly & Co. and Novo Nordisk A/S are competing for drug contracts in the aftermath of drug price scrutiny. Novo has managed to secure a contract with CVS, beating out its competitor. Other news is ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

Trump's Department of Commerce is looking into what it calls national security threats from overseas drug manufacturing, and Lilly CEO David Ricks has personally met with President Donald Trump in ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

The Zensights Federated Healthcare Advisory Panel explores how shifting global dynamics are reshaping access and strategic ...

Shares of Eli Lilly ( LLY -10.79%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...

The pharma industry’s reputation dropped slightly again among patient groups, largely due to drug pricing issues.

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its [tariff rollout]( ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...